DSGN has 36-month beta value of 1.84. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DSGN is 33.02M, and currently, short sellers hold a 7.24% ratio of that float. The average trading volume of DSGN on May 07, 2024 was 263.46K shares.
DSGN) stock’s latest price update
Design Therapeutics Inc (NASDAQ: DSGN)’s stock price has soared by 24.35 in relation to previous closing price of 3.65. Nevertheless, the company has seen a gain of 28.94% in its stock price over the last five trading days. GlobeNewsWire reported 2024-05-07 that CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York.
DSGN’s Market Performance
Design Therapeutics Inc (DSGN) has experienced a 28.94% rise in stock performance for the past week, with a 20.71% rise in the past month, and a 94.80% rise in the past quarter. The volatility ratio for the week is 4.99%, and the volatility levels for the past 30 days are at 6.84% for DSGN. The simple moving average for the last 20 days is 21.90% for DSGN’s stock, with a simple moving average of 48.73% for the last 200 days.
Analysts’ Opinion of DSGN
Piper Sandler, on the other hand, stated in their research note that they expect to see DSGN reach a price target of $6, previously predicting the price at $42. The rating they have provided for DSGN stocks is “Neutral” according to the report published on November 14th, 2023.
Wedbush gave a rating of “Neutral” to DSGN, setting the target price at $6 in the report published on August 15th of the previous year.
DSGN Trading at 34.04% from the 50-Day Moving Average
After a stumble in the market that brought DSGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.41% of loss for the given period.
Volatility was left at 6.84%, however, over the last 30 days, the volatility rate increased by 4.99%, as shares surge +14.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +48.78% upper at present.
During the last 5 trading sessions, DSGN rose by +21.73%, which changed the moving average for the period of 200-days by -41.78% in comparison to the 20-day moving average, which settled at $3.75. In addition, Design Therapeutics Inc saw 71.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DSGN starting from Schmid John P., who purchase 17,809 shares at the price of $3.74 back on Mar 25 ’24. After this action, Schmid John P. now owns 26,965 shares of Design Therapeutics Inc, valued at $66,606 using the latest closing price.
Berger Heather A., the Director of Design Therapeutics Inc, purchase 1,300 shares at $3.74 during a trade that took place back on Mar 25 ’24, which means that Berger Heather A. is holding 1,300 shares at $4,866 based on the most recent closing price.
Stock Fundamentals for DSGN
The total capital return value is set at -0.29. Equity return is now at value -22.10, with -21.20 for asset returns.
Based on Design Therapeutics Inc (DSGN), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -18.9. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 35.77.
Currently, EBITDA for the company is -78.19 million with net debt to EBITDA at 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 29.58.
Conclusion
To put it simply, Design Therapeutics Inc (DSGN) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
